Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $473000.0.

  • Bioventus' Capital Expenditures rose 63906.25% to $473000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 21910.11%. This contributed to the annual value of $1.0 million for FY2024, which is 8633.52% down from last year.
  • As of Q3 2025, Bioventus' Capital Expenditures stood at $473000.0, which was up 63906.25% from $683000.0 recorded in Q2 2025.
  • Bioventus' Capital Expenditures' 5-year high stood at $9.0 million during Q4 2021, with a 5-year trough of -$5.2 million in Q4 2022.
  • For the 5-year period, Bioventus' Capital Expenditures averaged around $1.3 million, with its median value being $1.3 million (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 15765.19% in 2022, then skyrocketed by 78701.3% in 2025.
  • Bioventus' Capital Expenditures (Quarter) stood at $9.0 million in 2021, then tumbled by 157.65% to -$5.2 million in 2022, then skyrocketed by 107.15% to $369000.0 in 2023, then soared by 55.56% to $574000.0 in 2024, then fell by 17.6% to $473000.0 in 2025.
  • Its last three reported values are $473000.0 in Q3 2025, $683000.0 for Q2 2025, and $826000.0 during Q1 2025.